跳转至内容
Merck
CN
  • Differentiation of human pluripotent stem cells into nephron progenitor cells in a serum and feeder free system.

Differentiation of human pluripotent stem cells into nephron progenitor cells in a serum and feeder free system.

PloS one (2014-04-15)
Minyong Kang, Yong-Mahn Han
摘要

Kidney disease is emerging as a critical medical problem worldwide. Because of limited treatment options for the damaged kidney, stem cell treatment is becoming an alternative therapeutic approach. Of many possible human stem cell sources, pluripotent stem cells are most attractive due to their self-renewal and pluripotent capacity. However, little is known about the derivation of renal lineage cells from human pluripotent stem cells (hPSCs). In this study, we developed a novel protocol for differentiation of nephron progenitor cells (NPCs) from hPSCs in a serum- and feeder-free system. We designed step-wise protocols for differentiation of human pluripotent stem cells toward primitive streak, intermediate mesoderm and NPCs by recapitulating normal nephrogenesis. Expression of key marker genes was examined by RT-PCR, real time RT-PCR and immunocytochemistry. Each experiment was independently performed three times to confirm its reproducibility. After modification of culture period and concentration of exogenous factors, hPSCs can differentiate into NPCs that markedly express specific marker genes such as SIX2, GDNF, HOXD11, WT1 and CITED1 in addition to OSR1, PAX2, SALL1 and EYA1. Moreover, NPCs possess the potential of bidirectional differentiation into both renal tubular epithelial cells and glomerular podocytes in defined culture conditions. In particular, approximately 70% of SYN-positive cells were obtained from hPSC-derived NPCs after podocytes induction. NPCs can also form in vitro tubule-like structures in three dimensional culture systems. Our novel protocol for hPSCs differentiation into NPCs can be useful for producing alternative sources of cell replacement therapy and disease modeling for human kidney diseases.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
视黄酸, ≥98% (HPLC), powder
Sigma-Aldrich
甲醛 溶液, Molecular Biology, 36.5-38% in H2O
Sigma-Aldrich
甲醛 溶液, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
SAFC
甲醛 溶液, contains 10-15% methanol as stabilizer, 37 wt. % in H2O
Supelco
胆钙化醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
胆钙化醇, ≥98% (HPLC)
Sigma-Aldrich
甲醛 溶液, Molecular Biology, BioReagent, ≥36.0% in H2O (T)
Sigma-Aldrich
甲醛 溶液, meets analytical specification of USP, ≥34.5 wt. %
Supelco
甲醛 溶液, stabilized with methanol, ~37 wt. % in H2O, certified reference material
Supelco
胆钙化固醇(维生素 D3), analytical standard
USP
胆钙化醇, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甲醛 溶液, tested according to Ph. Eur.
Supelco
维生素D3标准液 CRM 溶液, 1 mg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
胆钙化醇, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
胆钙化醇, meets USP testing specifications
Sigma-Aldrich
胆钙化醇, analytical standard
Sigma-Aldrich
甲醛-12C 溶液, 20% in H2O, 99.9 atom % 12C